GB0605785D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0605785D0
GB0605785D0 GBGB0605785.5A GB0605785A GB0605785D0 GB 0605785 D0 GB0605785 D0 GB 0605785D0 GB 0605785 A GB0605785 A GB 0605785A GB 0605785 D0 GB0605785 D0 GB 0605785D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0605785.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0605785.5A priority Critical patent/GB0605785D0/en
Publication of GB0605785D0 publication Critical patent/GB0605785D0/en
Priority to PCT/EP2007/052640 priority patent/WO2007107567A1/en
Priority to JP2009500854A priority patent/JP5256189B2/ja
Priority to US12/293,588 priority patent/US20110207777A1/en
Priority to ES07727117T priority patent/ES2395532T3/es
Priority to EP07727117A priority patent/EP1996189B1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0605785.5A 2006-03-22 2006-03-22 Compounds Ceased GB0605785D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0605785.5A GB0605785D0 (en) 2006-03-22 2006-03-22 Compounds
PCT/EP2007/052640 WO2007107567A1 (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine
JP2009500854A JP5256189B2 (ja) 2006-03-22 2007-03-20 Ｍ１受容体で活性を有するベンズイミダゾールおよび医薬におけるその使用
US12/293,588 US20110207777A1 (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine
ES07727117T ES2395532T3 (es) 2006-03-22 2007-03-20 BENCIMIDAZOLES que tienen actividad en el receptor M1 y sus usos en medicina
EP07727117A EP1996189B1 (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0605785.5A GB0605785D0 (en) 2006-03-22 2006-03-22 Compounds

Publications (1)

Publication Number Publication Date
GB0605785D0 true GB0605785D0 (en) 2006-05-03

Family

ID=36383994

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0605785.5A Ceased GB0605785D0 (en) 2006-03-22 2006-03-22 Compounds

Country Status (6)

Country Link
US (1) US20110207777A1 (https=)
EP (1) EP1996189B1 (https=)
JP (1) JP5256189B2 (https=)
ES (1) ES2395532T3 (https=)
GB (1) GB0605785D0 (https=)
WO (1) WO2007107567A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706168D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706187D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0817982D0 (en) * 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
CA2755561A1 (en) * 2009-03-26 2010-09-30 Mapi Pharma Limited Process for the preparation of alogliptin
CN110368375B (zh) * 2019-07-02 2021-10-01 青岛大学附属医院 用于抑郁症及相关病症的缓释组合物及其制备方法
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
WO1997016186A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine agonists
ATE275141T1 (de) * 1999-10-13 2004-09-15 Banyu Pharma Co Ltd Substituierte imidazolin-derivate
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
JP2005532361A (ja) * 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
GB0505304D0 (en) * 2005-03-15 2005-04-20 Ds Smith Plastics Ltd Tap for liquid containers
WO2007036711A1 (en) * 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR
BRPI0616609A2 (pt) * 2005-09-30 2011-06-28 Glaxo Group Ltd compostos que têm atividade no receptor m1, composição farmacêutica contendo tais compostos, processo para preparação dos mesmos, bem como seus usos em medicina
GB0605784D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0605786D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706189D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
JP2009530348A (ja) 2009-08-27
EP1996189A1 (en) 2008-12-03
WO2007107567A1 (en) 2007-09-27
US20110207777A1 (en) 2011-08-25
JP5256189B2 (ja) 2013-08-07
EP1996189B1 (en) 2012-09-26
ES2395532T3 (es) 2013-02-13

Similar Documents

Publication Publication Date Title
GB0602424D0 (en) Compounds
GB0602046D0 (en) Compounds
EP1984379A4 (en) ANTI-ARENAVIRAL COMPOUNDS
GB0605786D0 (en) Compounds
GB0606876D0 (en) Compounds
GB0614070D0 (en) Compounds
EP2082022A4 (en) COMPOUNDS
GB0607175D0 (en) Compounds
EP2004174A4 (en) NAPHTHALENEDIONED COMPOUNDS
GB0605785D0 (en) Compounds
GB0605784D0 (en) Compounds
GB0606913D0 (en) Compounds
GB0602042D0 (en) Compounds
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
GB0602560D0 (en) Compounds
EP1973905A4 (en) COMPOUNDS
GB0602412D0 (en) Compounds
GB0600427D0 (en) Compounds
GB0605414D0 (en) Compounds
GB0602856D0 (en) Compounds
GB0605588D0 (en) Compounds
GB0605540D0 (en) Compounds
GB0605539D0 (en) Compounds
GB0605467D0 (en) Compounds
GB0604375D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)